Fisetin Value Index 2026
A price-density ranking across 18 database entries where both a current captured price and a verified fisetin amount were available. Cheap milligrams are useful context, not a substitute for formulation quality.
Current value table
| Rank | Product | Fisetin/serving | Price | Cost/100 mg | Value Score | Transparency |
|---|---|---|---|---|---|---|
| 1 | Toniiq Senolytic+ 4000 | 1,400 mg | $29.97 | $2.14 | 10.0/10 | 10/10 |
| 2 | Neurogan Health Fisetin | 500 mg | $22.36 | $4.47 | 8.4/10 | 4/10 |
| 3 | ProHealth Longevity Rapid Reset Multi-Senolytic | 1,500 mg | $69.95 | $4.66 | 8.3/10 | 10/10 |
| 4 | Toniiq Fisetin 500 | 500 mg | $44.97 | $8.99 | 6.9/10 | 10/10 |
| 5 | Nature's Fusions Nutri Fisetin Extra Strength | 500 mg | $48.99 | $9.80 | 6.7/10 | 4/10 |
| 6 | Humanx Fisetin | 500 mg | $54.95 | $10.99 | 6.5/10 | 4/10 |
| 7 | Vitacost Fisetin Flavonoid | 100 mg | $11.96 | $11.96 | 6.3/10 | 5/10 |
| 8 | Swanson Vitamins Fisetin Novusetin | 100 mg | $17.89 | $17.89 | 5.4/10 | 4/10 |
| 9 | California Gold Nutrition Fisetin with BeFisetin | 100 mg | $21.74 | $21.74 | 5.0/10 | 8/10 |
| 10 | Nutricost Fisetin | 100 mg | $21.95 | $21.95 | 5.0/10 | 4/10 |
| 11 | ProHealth Longevity Pure Fisetin | 250 mg | $55.95 | $22.38 | 5.0/10 | 10/10 |
| 12 | Double Wood Fisetin Supplement | 100 mg | $22.92 | $22.92 | 4.9/10 | 10/10 |
| 13 | Doctor's Best Fisetin with Novusetin | 100 mg | $22.99 | $22.99 | 4.9/10 | 5/10 |
| 14 | DoNotAge.org Pure Fisetin | 400 mg | $95.00 | $23.75 | 4.8/10 | 6/10 |
| 15 | ProHealth Longevity Fisetin Pro Longevity Plus | 125 mg | $37.95 | $30.36 | 4.3/10 | 7/10 |
| 16 | California Gold Nutrition Fisetin with Novusetin | 100 mg | $36.69 | $36.69 | 3.9/10 | 8/10 |
| 17 | Toniiq Qova | 50 mg | $55.00 | $110.00 | 1.5/10 | 10/10 |
| 18 | Life Extension Bio-Fisetin | 8 mg | $11.25 | $140.62 | 1.0/10 | 5/10 |
How to use this index
The index is useful for conventional single-ingredient products where a price-per-milligram comparison has an obvious meaning. It is less useful for enhanced-bioavailability formulations and multi-senolytic stacks because those products are intentionally selling more than raw fisetin quantity. Read the Value Score beside Transparency and Evidence Match, not in isolation.
What the Value Index measures
The Fisetin Value Index compares products only when a verified Fisetin amount and a captured current price make a normalized cost calculation possible.
Why price per 100 mg is useful
A normalized cost helps distinguish a genuinely expensive product from a bottle that only looks expensive because it contains more total Fisetin.
Why value is not efficacy
A low cost per 100 mg does not prove stronger biological activity, better absorption, higher purity, or better clinical outcomes.
Why some products are excluded
Products with missing dose, unclear active amount, bundle pricing, or complex multi-ingredient formulas can produce misleading cost calculations.
How formulation affects interpretation
Liposomal or enhanced-bioavailability products may cost more per milligram because the commercial proposition is not simply raw Fisetin quantity.
How testing affects value
A lower-cost product with poor documentation may be less attractive than a more transparent product even if the normalized cost is lower.
How to use the index
Use the Value Index as one layer alongside Transparency, Evidence Match, serving structure, and personal suitability.
Update policy
Prices change frequently. The index should be refreshed when major retailers or manufacturers change list prices or pack sizes.
Update trigger 1
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 2
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 3
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 4
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 5
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 6
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 7
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 8
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 9
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 10
For Fisetin Value Index 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.